Hugely promising cancer drug dostarlimab is one step closer to being widely available, after the Food and Drug Administration granted it Breakthrough Therapy Designation status that, if successful, will expedite its path to market.
  • timbuck2themoon@sh.itjust.worksEnglish
    7·
    3 months ago

    Actually, given the cost of multiple radiation or chemo treatments this might be cheaper and thus more favored by insurance, etc.